Explore our writings
and Ideas

For years, science companies have struggled to maintain a consistent and engaging social media presence. The long periods between milestones, the difficulty of communicating complex scientific concepts, and the lack of "virality" inherent in this field create unique challenges.

Imagine walking into a business with outdated decor, faded posters, and dusty furniture. What impression would you get? Probably not a great one. Your website is the digital face of your company, and just like a physical storefront, it needs a refresh every now and then. But how do you know when it's time for a website redesign? And how much time, effort, and budget should you allocate?

Utah's Life Sciences industry is experiencing remarkable growth, fueled by a unique spirit of collaboration. A new video, commissioned by key players like the Governor's office, the Mayor's office, state trade associations, university systems, and the financial community, captures the essence of this thriving ecosystem. This video aims to showcase how Utah fosters success in biotech, medtech, and pharma through collaborative partnerships.

Artificial intelligence (AI) has permeated almost every industry, and drug discovery is no exception. The promises are tantalizing: faster development times, reduced costs, and potentially even the discovery of new drugs for previously untreatable diseases. But amidst the hype and excitement, crucial questions remain: Is AI drug discovery truly delivering on its promises? What are the challenges faced by companies in this space? And how are some companies, setting themselves apart?

In the ever-evolving world of biotech, staying afloat requires more than just groundbreaking science. It demands resilience, adaptability, and a knack for storytelling. This is the story of GeoVax ( $GOVX ), a company that emerged from the crucible of the AIDS crisis, weathered the storms of public opinion, and ultimately found its footing by embracing a consistent and strategic approach to communication.

The anti-obesity drug market is booming. Big Pharma companies like Eli Lilly & Co (LLY) and Novo Nordisk (NVO) are racing to develop and acquire products that target the GLP-1 receptor system, the key mechanism behind blockbuster drugs like Ozempic, Wegovy, and Mounjaro. With Goldman Sachs forecasting the market to reach a staggering $100 billion by 2030, the competition is fierce. But amidst these giants, a small Utah-based company called Biolexis is poised to disrupt the landscape with a fresh perspective and a promising pipeline of "metabolic longevity" products.